Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEthos Technologies Inc. Class A Common Stock

Ethos Technologies Inc. Class A Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
37.13 USD -3.75 ( 9.17%)
Last update at 2026-11-04T21:19:00Z
VOLUME
2646504
Market Cap
123.53M

Momentum Score

…

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
36.99
Low
40.94
High
52 Week Price Range
1.08
Low
2.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
40.88
Dividend Yield
-
Revenue TTM
0.59M
Revenue Per Share
0.01
Gross Profit TTM
-32.42M
Debt / Equity
0.17
ROE
-55.61%
Net Debt
-7.45M
ROCE
-45.53%
Diluted EPS TTM
-0.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -45.34M -33.78M -16.23M -23.76M -34.52M
Minority interest 0.01M 0.01M -0.17M -0.16M -0.16M
Net income -44.28M -32.46M -14.96M -22.24M -34.52M
Selling general administrative 13.98M 10.75M 9.07M 9.35M 12.44M
Gross profit 10.39M - 10.46M 0.42M 0.00M
Reconciled depreciation 1.70M 1.30M 1.27M 1.37M 0.75M
Ebit -48.10M -35.32M -17.18M -24.34M -33.57M
Ebitda -46.40M -34.02M -15.91M -22.98M -32.82M
Depreciation and amortization 1.70M 1.30M 1.27M 1.37M 0.75M
Operating income -46.40M -34.02M -15.91M -22.98M -32.82M
Other operating expenses 56.79M 34.02M 26.37M 23.40M 32.82M
Interest expense -1.70M 0.24M 0.00M 0.00M 0.00M
Tax provision - - - - 0.00M
Income tax expense -1.07M -1.31M -1.27M -1.53M -1.70M
Total revenue 10.39M 0.01M 10.46M 0.42M 0.00M
Total operating expenses 56.79M 34.02M 26.37M 23.40M 32.82M
Cost of revenue - - - - 0.00M
Total other income expense net 1.06M 0.24M -0.32M -0.79M -1.70M
Net income from continuing ops -45.34M -33.78M -16.23M -23.76M -34.52M
Net income applicable to common shares -45.34M -33.77M -16.22M -23.60M -34.52M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 122.07M 95.79M 115.54M 38.73M 36.19M
Other current assets 2.39M 2.95M 5.38M 2.02M 0.78M
Total liab 31.60M 24.50M 6.41M 7.24M 15.16M
Total stockholder equity 90.66M 71.28M 109.13M 31.48M 21.03M
Other current liab 23.12M 9.86M 4.00M 3.57M 2.38M
Common stock 0.06M 0.03M 0.03M 0.01M 0.00M
Capital stock 0.06M 0.03M 0.03M 0.01M 0.01M
Retained earnings -468.02M -417.63M -372.30M -338.53M -322.30M
Other assets 0.00M 3.36M 0.16M 0.00M 0.17M
Cash 22.54M 9.98M 2.34M 16.95M 9.21M
Total current liabilities 16.42M 13.86M 6.01M 5.86M 12.92M
Current deferred revenue -11.56M - - - 0.21M
Net debt -7.45M 1.55M -0.96M -14.71M -6.22M
Short term debt 1.33M 0.89M 0.98M 0.86M 9.49M
Short long term debt - - - - 8.74M
Short long term debt total 15.10M 11.53M 1.38M 2.24M 2.99M
Other stockholder equity 558.69M 489.32M 481.66M 370.04M 343.36M
Property plant equipment - 11.56M 1.81M 2.98M 4.09M
Total current assets 102.99M 81.09M 113.73M 35.74M 31.93M
Net tangible assets - 71.46M 109.13M 31.65M 21.18M
Short term investments 75.62M 56.16M 105.58M 14.74M 21.93M
Net receivables 2.44M 11.78M 0.43M 2.04M 0.10M
Inventory -78.01M -2.95M - - -
Accounts payable 3.53M 3.11M 1.03M 1.43M 0.85M
Accumulated other comprehensive income -0.07M -0.43M -0.26M -0.04M -0.04M
Common stock total equity - - - 0.01M 0.00M
Non currrent assets other 0.13M 3.14M 0.16M 0.21M 0.17M
Non current assets total 19.07M 14.70M 1.81M 2.98M 4.26M
Capital lease obligations 15.10M 11.53M 1.38M 2.24M 2.99M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 47.24M -91.42M 6.90M 4.92M 37.17M
Change to liabilities 6.74M 0.05M 1.55M 0.37M -2.06M
Total cashflows from investing activities 47.24M -91.57M 6.90M 4.92M 37.17M
Net borrowings -0.07M -0.07M -9.08M -8.00M -4.67M
Total cash from financing activities 5.45M 110.03M 16.14M 1.34M -4.24M
Change to operating activities 4.35M -4.24M -1.88M -0.22M 0.66M
Net income -45.34M -33.78M -16.23M -23.76M -34.52M
Change in cash 10.81M -14.62M 7.74M -13.75M 1.87M
Begin period cash flow 2.34M 16.95M 9.21M 22.96M 21.09M
End period cash flow 13.15M 2.34M 16.95M 9.21M 22.96M
Total cash from operating activities -41.89M -33.08M -15.30M -20.01M -31.06M
Issuance of capital stock 5.47M 109.95M 25.22M 9.32M 0.38M
Depreciation 1.70M 1.30M 1.27M 1.37M 0.75M
Other cashflows from investing activities - - - 5.00M 37.77M
Dividends paid - - -0.01M -0.01M 0.04M
Change to account receivables -11.92M 1.60M -1.94M 0.06M -0.05M
Sale purchase of stock 0.04M - 0.01M 0.01M 0.04M
Other cashflows from financing activities 0.00M 0.07M 0.01M 0.01M 0.05M
Change to netincome 2.59M 1.98M 1.57M 1.31M 3.19M
Capital expenditures 1.64M 0.19M 0.20M 0.08M 0.59M
Change in working capital -0.83M -2.59M -2.26M 0.21M -1.45M
Stock based compensation 2.15M 1.61M 1.47M 1.78M 3.43M
Other non cash items 0.44M 0.37M 0.35M 0.71M 0.97M
Free cash flow -43.53M -33.27M -15.50M -20.09M -31.66M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LIFE
Ethos Technologies Inc. Class A Common Stock		 -3.75
9.17%		 37.13 - - 334.89 1.30 99.56 -0.67
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Ethos Technologies Inc. Class A Common Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

10240 Sorrento Valley Road, San Diego, CA, United States, 92121

858 731 8389

https://www.atyrpharma.com

56

Name Title Year Born
Dr. Sanjay S. Shukla M.D., M.S. Pres, CEO & Director 1972
Ms. Jill M. Broadfoot Chief Financial Officer 1962
Ms. Nancy E. Denyes Krueger Gen. Counsel & Corp. Sec. 1968
Xiang-Lei Yang Ph.D. Founder NA
Ms. Ashlee Dunston Director of Investor Relations & Corp. Communications NA
Mr. Peter Villiger VP of Corp. Devel. NA
Ms. Danielle Campbell VP of Human Resource NA
Dr. Leslie Nangle Ph.D. VP of Research NA
Dr. Ying J. Buechler Ph.D. Exec. Director of Biologics Devel. & Manufacturing NA
Dr. Melissa A. Ashlock Sr. Advisor 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…